GeneThera, Inc.

Equities

GTHR

US37185E3062

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 11:44:13 20/02/2024 pm IST			5-day change	1st Jan Change
0.000001 ^USD	-99.98%		-.--%	-.--%

2022	GeneThera, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	CI
2022	GeneThera, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	CI

Genethera, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020

April 15, 2021 at 12:04 am IST

GeneThera, Inc. announced earnings results for the full year ended December 31, 2020. For the full year, the company announced operating loss was USD 740,611 compared to USD 739,152 a year ago. Net loss was USD 774,463 compared to USD 517,651 a year ago. Basic loss per share from continuing operations was USD 0.04 compared to USD 0.01 a year ago.

Latest news about GeneThera, Inc.

GeneThera, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/22/14	CI
GeneThera, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	18/22/18	CI
GeneThera, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	18/22/18	CI
GeneThera, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	14/22/14	CI
GeneThera, Inc. Auditor Raises 'Going Concern' Doubt	14/22/14	CI
GeneThera, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	15/21/15	CI
GeneThera Inc. Enters into an exclusive real estate agreement with Cushman & Wakefield related to the ZIDAS project	12/21/12	CI
Genethera, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	17/21/17	CI
GeneThera, Inc. announced a financing transaction	18/21/18	CI
Genethera, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	13/21/13	CI
GeneThera Enters into Collaboration Agreement with Cumming Corporation to Build Network of Zoonotic Diseases Laboratory Facilities	27/21/27	CI
Genethera, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	15/21/15	CI
Genethera, Inc. Announces Platform for Wastewater Testing	06/21/06	CI
Genethera, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	17/20/17	CI
Genethera, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	15/20/15	CI
Genethera, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	25/20/25	CI
Genethera, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	11/20/11	CI
GeneThera, Inc. Announces Resignation of Fred Oeschger from the Board of Directors	14/18/14	CI
GeneThera, Inc. Announces Directorate Changes	01/18/01	CI
GeneThera Inc. Secures New Laboratory Facilities to Expand Technology Platforms	25/16/25	CI
GeneThera Inc. Announces Board Appointments	21/15/21	CI
GeneThera, Inc. Auditor Raises 'Going Concern' Doubt	14/15/14	CI
GeneThera Inc. Enters into Exclusive Collaboration Agreement with Hudson Robotics Inc	04/15/04	CI
GeneThera Inc. Auditor Raises 'Going Concern' Doubt	16/14/16	CI
GeneThera Inc. will Change its Ticker to GTHR from GTHR.E	17/13/17	CI

Chart GeneThera, Inc.

Duration

Period

More charts

Company Profile

GeneThera, Inc. is a biotechnology company. The Company is focused on developing genetics-based diagnostic assays and vaccine solutions and molecular diagnostic tests, therapeutics, and vaccines through its technologies for controlling the spread of zoonotic infection. The Company has developed a Molecular Robotic/AI Laboratory Platform (MORAP), which combine the use of advanced robotic laboratory systems integrated with artificial intelligence software systems. Its MORAPAT is designed to prevent the spread of disease from animals and control zoonotic infectious agents. The Company has also developed a large-scale process for highly purified and high viral titer (viral concentration) Adenovirus and Adeno-associated virus (AAV) genetically engineered viruses. This technology develops Adenovirus and AAV-based recombinant DNA vaccines for zoonotic pathogens. PURIVAX is a purification system that enhances biological purity and viral titer of recombinant Adenovirus and AAV vectors.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
GENETHERA, INC.	-.--%	35
MODERNA, INC.	+23.37%	47.02B
LONZA GROUP AG	+48.83%	41.86B
IQVIA HOLDINGS INC.	-0.94%	41.76B
CELLTRION, INC.	-5.86%	28.8B
ICON PUBLIC LIMITED COMPANY	+11.29%	26.05B
ALNYLAM PHARMACEUTICALS, INC.	-20.92%	19.15B
BIO-TECHNE CORPORATION	+3.20%	12.55B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.67%	11.82B
MEDPACE HOLDINGS, INC.	+30.23%	12.34B

Other Biotechnology & Medical Research